Latest News Biotech Firm Aurion Biotech Names Greg Kunst Chief Executive Officer By Staff Thursday, June 10, 2021 12:24 AM SEATTLE and BOSTON—Greg Kunst has been named chief executive officer of newly launched Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases. The company’s first candidate is a cell therapy for the treatment of corneal endothelial disease, which affects millions of people worldwide, with symptoms that include blurred vision, glare, discomfort and pain. Invented by world-renowned ophthalmic surgeon and research scientist Professor Shigeru Kinoshita and his distinguished colleagues at Kyoto Prefecture University of Medicine (KPUM) in Japan, corneal endothelial cell therapy has demonstrated long-term efficacy in Phase 2 and Phase 3 studies in Japan. “I am delighted to join Aurion Biotech because we have all the key ingredients for success—the best science, the best scientists and medical advisors, and the best backers,” Kunst said in an announcement.“Our lead candidate, in early research and Phase 2 and Phase 3 studies in Japan, has already demonstrated long-term, significant improvements in patients’ vision. I look forward to scaling up our team to pursue clinical development in the U.S. and around the world, and to build a platform of transformational biotechnologies with the aim of restoring vision to all patients who need it.” Kunst has varied experience in ophthalmic medical devices, drug delivery systems, diagnostics, biotechnology, and pharmaceutical products. His expertise spans global corporate development, strategy, health policy, marketing, commercialization, business development, market access and medical affairs. Before Aurion Biotech, Kunst spent six years at Glaukos Corporation (NYSE: GKOS), where he led the worldwide marketing, market access, reimbursement, health economics and outcomes research, government affairs, and business development teams. Based in Seattle and Boston, Aurion Biotech is a clinical stage biotech company with a mission to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies.